Legend Biotech Corporation engages in the discovery and development of novel cell therapies for oncology and other indications in the United States,China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for gastric cancer and T cell lymphoma.
